Vyome Holdings, Inc. HIND
1.58 USD -0.03 (-1.86%)
At closeNov 6, 2026, 4:00 PM EST
1.60 +0.02 +1.20%
After hours · Nov 6, 4:00 PM ET
1.57 Day range 1.66
1.58 52-week range 5.73
- YTD
- -54.07%
- 1 year
- -72.08%
- Market cap
- 11.09M
- EPS (ttm)
- 1.78
- P/E ratio
- 0.89
- YTD return
- -54.07%
- 1-year return
- -72.08%
- Volume
- 19.78K
- Avg volume
- 13.65K
- Open
- 1.66
- Previous close
- 1.61
- Day's range
- 1.57 – 1.66
- 52-week range
- 1.58 – 5.73
ALL -106,139,998.42 (-100.00%)
Financials — quick view
HIND Revenue — quarterly 26.95K
HIND Net income — quarterly -685.56K
HIND EPS — quarterly -0.09
News
Vyome Holdings' ReShape Lifesciences Has Received A Notice Of Allowance For A U.S. Patent Titled "VAGUS NERVE NEUROMODULATION FOR THE TREATMENT OF THE HYPOGLYCEMIC STATE". 
Vyome Holdings Appoints Jerry Leonard As CFO, Succeeding Robert Dickey IV, Who Served As Interim CFO Since August 2025 
Chardan Capital Initiates Coverage On Vyome Holdings with Buy Rating, Announces Price Target of $3.5 
Vyome Appoints Jerry Leonard As CFO On August 27, 2026 
12 Health Care Stocks Moving In Friday's After-Market Session - China National Intellectual Property Administration Grants Vyome Patent Chinese Patent No. ZL 2021 1 0758695.X
- Vyome Holdings Reports Data On Its Phase 2 Investigator Initiated Trial Results, Preclinical Data Of VT-1953 To Treat Symptoms Of Malignant Fungating Wounds At American Association For Cancer Research Annual Meeting
Vyome Holdings To Present Full Phase 2 Investigator Initiated Study Results And Preclinical Data Supporting Efficacy And Safety Of VT-1953 As Potential Treatment For Malodor And Other Symptoms Of MFW At 2026 AACR - 12 Health Care Stocks Moving In Thursday's After-Market Session
Vyome Files For Orphan Drug Status For VT-1953, Its Lead Clinical Program
Your note
Sign in to keep a note on HIND — it syncs with the Stock Master app.